Animal models for evaluating pharmaceutical compounds

US10729791B2 · kind B2 · utility

Assignee

• IMCYSE SA · BE

Inventors

• Jean-Marie Saint-Remy · Grez-Doiceau, BE
• Luc Vander Elst · Obaix, BE
• Vincent Carlier · Énines, BE

Key dates

• Filing date: May 11, 2016
• Grant date: Aug 4, 2020
• Expiry date: Sep 12, 2036

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A01K2267/0387
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The application relates to methods for determining a parameter such as toxicity and pharmacokinetic behavior for a pharmaceutical compound against a disease or disorder. The test animals being used are non-human animals not suffering from or is not showing symptoms or signs of the disorder and which do not provoke an immune response against said pharmaceutical compound. These animals are obtainable by administration of a peptide comprising an oxidoreductase motif further comprising an NKT peptide epitope or an MHC class II T cell epitope of said pharmaceutical compound, wherein said motif and said epitope are separated by a linker of between 0 and 4 amino acids.